Laccase mutants
    71.
    发明授权
    Laccase mutants 有权
    漆酶突变体

    公开(公告)号:US06218170B1

    公开(公告)日:2001-04-17

    申请号:US09518901

    申请日:2000-03-06

    申请人: Allan Svendsen

    发明人: Allan Svendsen

    IPC分类号: C12N120

    摘要: The present invention relates to laccase mutants with increased oxidation potential and/or changed pH optimum and/or altered mediator pathway and/or altered O2/OH− pathway.

    摘要翻译: 本发明涉及具有增加的氧化电位和/或改变的pH最佳和/或改变的介体途径和/或改变的O 2 / OH途径的漆酶突变体。

    DNA sequences encoding insulin precursors and methods of production
    73.
    发明授权
    DNA sequences encoding insulin precursors and methods of production 失效
    编码胰岛素前体的DNA序列和生产方法

    公开(公告)号:US5324641A

    公开(公告)日:1994-06-28

    申请号:US952696

    申请日:1992-09-23

    CPC分类号: C07K14/62 A61K38/00

    摘要: DNA molecule and process for producing insulin precursors having the formula B(1-29) -H.sub.1 --X.sub.2 --Y.sub.2 --Y.sub.1 --A(1-21), wherein B(1-29) are the 29 first amino acid residues of the B chain of human insulin starting from the N-terminus, A(1-21) are the 21 amino acid residues of the A chain of human insulin, X.sub.1 represents a peptide bond or one naturally-occurring alpha-amino acid acid residues, X.sub.2 represents Glu or Asp, and Y.sub.1 and Y.sub.2 each represent Lys or Arg, the positions A6 and A11, A7 and B7 and A20 and B19, respectively, are connected through sulphur bridges, and, if desired, one or more of the glutamic acid residues in positions A4, A17, B13 and B21 are substituted by another naturally-occurring alpha-amino acid residue having an uncharged side chain, are provided. The insulin precursors are prepared by culturing a yeast strain transformed with a replicable plasmid comprising a DNA sequence encoding an insulin precursor of the above formula in a suitable medium and isolating the insulin precursor thus formed from the culture medium. The insulin precursor can be converted into human insulin or insulin analogues by enzymatic treatment in a manner known per se.

    摘要翻译: DNA分子和具有式B(1-29)-H1-X2-Y2-Y1-A(1-21)的胰岛素前体的制备方法,其中B(1-29)是B的第一个氨基酸残基 A(1-21)是人胰岛素A链的21个氨基酸残基,X1表示肽键或一个天然存在的α-氨基酸酸残基,X2表示 Glu或Asp,Y1和Y2各自表示Lys或Arg,位置A6和A11,A7和B7和A20和B19分别通过硫桥连接,如果需要,一个或多个谷氨酸残基在 位置A4,A17,B13和B21被另一个具有不带电侧链的天然存在的α-氨基酸残基所取代。 通过在合适的培养基中培养用包含编码上式胰岛素前体的DNA序列的可复制质粒转化的酵母菌株并分离由培养基形成的胰岛素前体来制备胰岛素前体。 胰岛素前体可以通过本身已知的方式通过酶处理转化为人胰岛素或胰岛素类似物。

    Lipolytic enzymes
    75.
    发明授权
    Lipolytic enzymes 有权
    脂肪分解酶

    公开(公告)号:US09115346B2

    公开(公告)日:2015-08-25

    申请号:US12826960

    申请日:2010-06-30

    IPC分类号: C12N9/00 A61K38/43 C12N9/20

    CPC分类号: C12N9/20 C12Y301/01003

    摘要: The inventors have developed a method using protein engineering to produce lipolytic enzymes having a relatively high activity for one ester bond in an amphiphilic substrate with two lipophilic groups) and a relatively low activity for the ester bond in an amphiphilic substrate with one lipophilic group, e.g. a relatively high phospholipase activity and a relatively low lysophospholipase activity.

    摘要翻译: 本发明人开发了一种使用蛋白质工程的方法来生产对于具有两个亲脂基团的两亲底物中的一个酯键具有相对较高活性的脂肪分解酶),并且在具有一个亲油基团的两亲底物中具有较低的酯键活性。 相对较高的磷脂酶活性和较低的溶血磷脂酶活性。